Asiatic Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-12-2024
- Paid Up Capital ₹ 9.14 M
as on 15-12-2024
- Company Age 20 Year, 18 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 412.59%
(FY 2022)
- Profit 57.95%
(FY 2022)
- Ebitda 24.21%
(FY 2022)
- Net Worth -37.44%
(FY 2022)
- Total Assets -42.02%
(FY 2022)
About Asiatic Clinical Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 9.14 M, as per Ministry of Corporate Affairs (MCA) records.
Venkataraman Srinivasan, Bindhu Aravapalli, and Kunigal Ravi serve as directors at the Company.
- CIN/LLPIN
U85110KA2005PTC035360
- Company No.
035360
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jan 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Asiatic Clinical Research Private Limited offer?
Asiatic Clinical Research Private Limited offers a wide range of products and services, including Data Entry & Data Processing Service, Data Management, Architectural & Civil Engineering, Architectural Services, Copywriting & Content Development, Content Writing Service, Pharma & Bioanalytical Services, Pharmaceutical Services, Company Law & Labour Law Consultants, Statutory Compliance Services.
Who are the key members and board of directors at Asiatic Clinical Research?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkataraman Srinivasan  | Director | 15-Sep-2010 | Current |
| Bindhu Aravapalli | Director | 03-Jan-2005 | Current |
| Kunigal Ravi | Director | 29-Feb-2020 | Current |
Financial Performance of Asiatic Clinical Research.
Asiatic Clinical Research Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 412.59% increase. The company also saw a substantial improvement in profitability, with a 57.95% increase in profit. The company's net worth observed a substantial decline by a decrease of 37.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asiatic Clinical Research?
In 2022, Asiatic Clinical Research had a public holding of 8.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Asiatic Clinical Research?
Unlock and access historical data on people associated with Asiatic Clinical Research, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asiatic Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asiatic Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
